Ability of protein epitope-containing constructs associated with melanoma to stimulate the cytotoxic activity of peripheral blood mononuclear cells against melanoma cells

Aim. The aim of the study was to evaluate the ability of pMEL-TCI and pMEL-A0201 DNA-constructs encoding artificial polyepitope melanoma antigens to induce antitumor T cell immune response ex vivo. material and methods. Dendritic cells were obtained from peripheral blood mononuclear cells of HLA-A02:01-positive donors; DCs transfected with target DNA vaccine constructions were co-cultured with autologous T lymphocytes to stimulate anti-tumor effector T cells. Specific activity of ex vivo stimulated PBMC was assessed (1) by their ability to cause lysis of human melanoma Mel Is cells, and (2) by the level of their granzyme-producing activity. A recombinant plasmid encoding the full-length MART-1 melanoma antigen was used as a positive control. results. All DNA vaccine constructions as well as positive control construction were found to be able to stimulate specific anti-tumor immune responses of autologous PBMC ex vivo, and these PBMC were found to induce melanoma Mel Is cells lysis. Both the efficiency of induced cytotoxic responses and the level of granzymes production stimulated with DCs transfected with pMel-A0201 significantly exceeded those stimulated with DCs transfected with either pMel-TCI or with DNA construction encoding the full-length MART-1 protein. The cytotoxicity level correlates with the level of granzyme B production in CD8+ T lymphocytes. conclusion. DNA vaccine constructions encoding artificial polypeptides composed of tumor antigen epitopes can stimulate the antitumor cytotoxic response. This approach can be used as the basis for the development of new methods of immunotherapy for cancer.

melanoma, dna-vaccine constructs, t-cell epitopes, artificial immunogens, cytotoxic t-lymphocytes, skin melanoma, immunogens, cytotoxic activity, immune response

1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018 Jan; 68 (1): 7–30. doi: 10.3322/caac.21442.

2. Halama N., Zoernig I., Jaeger D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol. 2010; 2010: 689893. doi: 10.1155/2010/689893.

3. Pandolfi F., Cianci R., Lolli S., Dunn I.S., Newton E.E., Haggerty T.J., Boyle L.A., Kurnick J.T. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol. 2008 Jul‐ Sep; 21 (3): 493–500.

4. Parmiani G. Melanoma antigens and their recognition by T cells. Keio J Med. 2001 Jun; 50 (2): 86–90.

5. Denapoli P.M., Zanetti B.F., dos Santos A.A., de Moraes J.Z., Han S.W. Preventive DNA vaccination against CEA‐expressing tumors with anti‐idiotypic scFv6. C4 DNA in CEA‐expressing transgenic mice. Cancer Immunol Immunother. 2017 Mar; 66 (3): 333–342. doi: 10.1007/ s00262‐016‐1940‐4.

6. Antonets D.V., Bazhan S.I. PolyCTLDesigner: a computational tool for constructing polyepitope T‐cell antigens. BMC Res Notes. 2013 Oct 10; 6: 407. doi: 10.1186/1756‐0500‐6‐407.

7. Antonets D., Maksyutov A. TEpredict: software for T‐cell epitope prediction. Mol Biol (Mosk). 2010 Jan‐Feb; 44 (1): 1309.

8. Боробова Е.А., Антонец Д.В., Старостина Е.В., Смирнова О.Ю., Щербаков Д.Н., Волкова О.Ю., Орешкова С.Ф., Карпенко Л.И., Ильичев А.А., Бажан С.И. Кандидаты ДНК‐вакцины против меланомы: дизайн, конструирование и оценка экспрессии целевых генов в эу‐ кариотических клетках. Вестник Новосибирского государственного университета. Серия: биология, клиническая медицина. 2012; 10 (5): 23–30. [Borobova E.A., Antonets D.V., Starostina E.V., Smirnova O.Yu., Scherbakov D.N., Volkova O.Yu., Oreshkova S.F., Karpenko L.I., Ilyichev A.A., Bazhan S.I. Candidates of DNA vaccine against melanoma: design, engineering and estimating the expression of target genes in eukaryotic cells. Vestnik NGU. Seriya: Biologiya, klinicheskaya meditsina. 2012; 10 (5): 23–30. (in Russian)].

9. R Development Core Team. R: A language and environment for statistical computing [Internet]. URL: https://www.R‐project.org. (cited: 06.08.2018).

10. Villalobos A., Welch M., Minshull J. In silico design of func‐ tional DNA constructs. Methods Mol Biol. 2012; 852: 197–213. doi: 10.1007/978‐1‐61779‐564‐0_15.

11. Bazhan S.I., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Karpenko L.I., Nekrasova N.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Aborneva I.V., Ilyichev A.A. Designing and engineering of DNA‐vaccine construction encoding multiple CTL‐epitopes of major HIV‐1 antigens. Vaccine. 2004 Apr 16; 22 (13–14): 1672–82. doi: 10.1016/j.vaccine.2003.09.048.

12. Berzofsky J., Berkower I. Novel approaches to peptide and en‐ gineered protein vaccines for HIV using defined epitopes: advances in 19941995. AIDS. 1995; 9 Suppl A: S143–57.

13. Cardinaud S., Bouziat R., Rohrlich P.S., Tourdot S., Weiss L., Langlade-Demoyen P., Burgevin A., Fiorentino S., van Endert P., Lemonnier F.A. Design of a HIV‐1‐derived HLA‐B07. 02‐restricted poly‐ epitope construct. AIDS. 2009 Sep 24; 23 (15): 1945–54. doi: 10.1097/ QAD.0b013e32832fae88.

14. Iglesias M.C., Mollier K., Beignon A.S., Souque P., Adotevi O., Lemonnier F., Charneau P. Lentiviral vectors encoding HIV‐1 polyepitopes induce broad CTL responses in vivo. Molr Ther. 2007; 15 (6): 1203–10. doi: 10.1038/sj.mt.6300135.

15. Tine J.A., Firat H., Payne A., Russo G., Davis S.W., Tartaglia J., Lemonnier F.A., Demoyen P.L., Moingeon P. Enhanced multiepitope‐based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine. 2005; 23 (8): 1085–91. doi: 10.1016/j. vaccine.2003.01.001.

16. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A., Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV)polytopevaccinecontainingmultipleHLAA2HIVCD8+cytotoxic T‐cell epitopes. J Virol. 1999; 73 (7): 5320–5.